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Abstract 
Current prognostic indicators are ineffective for identifying advanced stage colorectal cancer 
(CRC) patients with high risk of recurrence after surgical resection.  We investigated the 
prognostic value of p53, Ki-67, and programmed death ligand 1 (PD-L1) in 254 patients with 
stage II and III CRC. The expression of p53 was positive in 63% of cases. Up-regulation of p53 
was associated with smaller tumor size (P=0.001) and higher Ki-67 labeling index (LI) 
(P=0.031). The tumor Ki-67 LI was high (≥ 20%) in 197 (78%) of the patients. High Ki-67 LI 
was associated with higher TNM stage (P=0.031), positive p53 expression (P=0.031), and 
negative PD-L1 expression (P=0.003). The five-year relapse-free survivals (RFS) were 53% and 
89%, respectively, for the p53-positive and Ki-67 LI-high patients and the p53-negative and Ki-
67 LI-low patients (P<0.001). In univariate analysis, negative p53 (P= 0.001), low Ki-67 LI 
(P=0.006), low PD-L1 expression (P=0.044), low TNM stage (P<0.001), recto-sigmoid location 
(P=0.026), and small size (P=0.013) were significantly related to RFS. In multivariate Cox 
regression analysis, positive p53 expression (hazard ratio [HR]: 2.48; 95% confidence interval: 
1.34-4.59, P= 0.004), high Ki-67 LI (HR: 2.62; 95% CI: 1.12-6.14, P=0.027) and high TNM 
stage (HR: 2.598, 95% CI: 1.55-4.37, P<0.001,) were independent predictors of unfavorable 
prognosis. In summary, PD-L1, Ki-67, and p53 staining individually had significant prognostic 
value for patients with stage II and III CRC. Moreover, combining p53 H-score ≥ 35 and Ki-67 
LI ≥ 20% identifies patients with poor clinical outcome. 
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Introduction 
Colorectal cancer (CRC) is the third most common cancer in the world, and its burden is 
expected to increase 60% by 2030 to more than 2.2 million new cases and 1.1 million deaths (1-
3). Current prognostic factors are still insufficient for identifying patients at high risk of 
recurrence after surgery for stage II and III disease. These patients may benefit from aggressive 
adjuvant treatment. It would also be desirable to identify patients at low risk of recurrence who 
may safely be spared the morbidity and expense of adjuvant interventions after surgery (4-7).  
TP53, a well-known tumor suppressor gene, encodes a nuclear protein that is a nexus for 
responses to various cellular stresses. Activation of the p53 pathway results in cell cycle arrest, 
apoptosis, or senescence (8). Inactivation of p53 is a key event in CRC progression and 
correlates with transitions from benign adenomas to malignant carcinomas (9). Although many 
investigations have addressed the prognostic value of p53 in CRC patients, no consistent 
conclusions have been drawn (10, 11). Cellular proliferation rate may be another tool to stratify 
CRC risk groups. The MIB-1 antibody recognizes an epitope on the Ki-67 cell cycle progression 
protein and is frequently used to measure proliferation or to predict behavior for many 
malignancies. In CRC patients, however, the Ki-67 index has not always had a significant 
association with clinical outcome (11). Finally, antitumor immune responses portend a favorable 
outcome for many tumors (12). Multiple cancer types implement an “immune shield” against 
inflammatory cell attack by expressing programmed death ligand 1 (PD-L1). This surface 
receptor on the tumor cell generates an immunosuppressive microenvironment and allows the 
tumor cell with foreign epitopes to escape immune-mediated destruction (13). PD-L1 ligand 
binding to programmed death-1 (PD-1) receptors on T-cells results in suppression of CD-8+ 
antigen-specific cytotoxic cell proliferation and causes apoptosis of PD-1 positive lymphocytes. 
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PD-L1 expression in tumor specimens is used as a predictive marker for tumor response to anti-
PD-1 or anti-PD-L1 immunotherapy (14-16). The present investigation was designed to assess 
the value of using p53 and Ki-67 as prognostic markers either alone or in combination with PD-
L1 in patients with stage II and III CRC.  
 
Materials and Methods 
Patients 
Tumor samples were obtained from 254 consecutive patients who had undergone surgical 
resection for CRC without preoperative treatment at the Fudan University Shanghai Cancer 
Center (FUSCC) from 2007 through 2009. The inclusion criteria were as follows: primary 
sporadic colorectal adenocarcinoma (mucinous carcinoma and other less common variant types 
were excluded), 28-75 years of age, and no preoperative chemotherapy or radiotherapy (17). 
Patients were included if the final pathology report of the CRC included the tumor location, 
whether colo-cecal or recto-sigmoid, and tumor size by greatest dimension, whether lateral or 
radial. The patients were staged according to the American Joint Committee on 
Cancer/International Union against Cancer (AJCC/UICC) TNM staging system (2010, 7th 
edition) (18). All the patients had advanced-stage colorectal cancer (≥ T2). Histologic grading 
(differentiation) was based on the 2010 WHO classification of tumors of the digestive system 
(4th edition) (19). The study was carried out with the approval of the local Ethics Committee of 
FUSCC. 
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Tissue Microarray and Immunohistochemistry 
Tissue microarrays (TMA) were constructed from paraffin-embedded blocks of the 254 
CRC primary tumors as previously described(17). Each case in the TMA was represented in 
duplicate cores, 1 mm in size for each core. Each TMA block contained 118 individual tissue 
cores. Immunoreaction for p53 (DO-7 clone; Dako, Carpinteria, CA, USA; prediluted), Ki-67 
(MIB-1 clone; Dako, Carpinteria, CA; prediluted) and PD-L1 (SP142, Spring Bioscience, 
Pleasanton, CA, USA; pre-diluted) were performed using the FLEX Detection System (Dako, 
Carpinteria, CA). Diaminobenzidine (3, 3-diaminobenzidine) was used as the chromogen. For 
antigen retrieval EnVisionTM FLEX Target Retrieval (Tris/EDTA) Solution, high pH (Dako, 
Carpinteria, CA) was used. Immunostaining was performed on the DAKO Autostainer Plus 
(EnVisionTM FLEX+). Positive and negative controls were stained concurrently and showed 
appropriate immunostaining. PD-L1 expression was assessed in tumor cells as well as tumor-
infiltrating immune cells (i.e., immune cells present both within the tumor and around the tumor 
periphery) (17). IHC evaluation considered p53 and Ki-67 expression only in the nuclei of tumor 
cells (Figure 1). The interpretation of immunoreactivity for p53 was evaluated using the “hybrid 
scoring system” (H-score) criteria. An H-score was calculated as the sum of the product of the 
staining intensity in tumor cells (0, no staining; 1, weak staining; 2, moderate staining; 3, intense 
staining) and the proportion of cells showing that staining intensity (0–100%). If more than one 
staining intensity was present, the H-score was the sum of the h-scores for each intensity level. 
Thus, the possible H-score ranged from 0 to 300(20). Currently there is no consensus cutoff for 
p53 immunohistochemistry in CRC. In this study, cutoff score for p53 positivity was optimized 
using receiver operating characteristic (ROC) curve analysis (Figure 2). An H-score ≥ 35 
defined a positive p53 expression; and an H-score <35 defined a negative p53 expression. For 
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Ki-67 labeling index (LI), each TMA core was scored based on the percentage of positively 
stained malignant nuclei regardless of stain intensity. Immunoreactivity to Ki-67 was “low” if 
nuclear staining of tumor cells was <20% (Ki-67 LI-low) and “high” if ≥20% (Ki-67 LI-high), as 
previously described (21). For each tissue sample, H-score for p53 and Ki-67 LI was averaged 
across evaluable TMA tissue cores. 
 
Statistical Analysis 
To determine the association of p53 expression with clinico-pathological features, cutoff 
scores were determined by ROC curve analysis. The ROC curve is a plot of the sensitivity and 
(1-specificity) for an outcome at each value of the protein expression score. An H-score can 
therefore be selected from the curve such that a cutoff at this value leads to the greatest number 
of patients correctly classified as with (maximizing sensitivity) and without (maximizing 
specificity) the clinical end point (22). ROC curve analysis was performed for stages and 
survival. The most frequently obtained H-score was selected as the final cutoff score above 
which tumors should be considered positive for the outcome (23). χ² tests were used to determine 
the association between p53 and Ki-67 expression with clinic-pathological  characteristics, 
whereas the Kaplan-Meier method and log-rank test were used for univariate survival analysis. 
Cox proportional hazards regression was carried out for multivariable survival analysis. Hazard 
ratios (HR) and 95% confidence intervals (CI) were obtained. A two sided P value of ≤0.05 was 
considered statistically significant. All analyses were carried out using SPSS 22.0. 
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Results 
Clinicopathologic Characteristics 
A total of 254 CRC specimens were included in this study. The ages of the patients 
ranged from 28 to 75 years (median 56 years). The mean follow-up time was 42 months (range 
21-68 months). Sixty-eight patients (28%) had relapsed at the time of last follow-up. The 
metastatic sites included lung (n = 23), liver (n = 22), bone (n = 8), abdomen (n = 7), brain (n = 
3), and other organs (n=5).  
 
Correlation of p53 and Ki-67 Expression with Other Clinicopathologic Variables 
The association of p53 and Ki-67 expression with clinicopathologic parameters is 
summarized in Table 1. The prevalence of positive p53 expression was 63%. Notably, up-
regulation of p53 was associated with greater tumor size (P=0.001) and high Ki-67 LI (P=0.031). 
There was no significant relationship between p53 expression and gender, age, location, 
differentiation, lymphovascular invasion (LVI), perineural invasion (PNI), TNM stage, pT stage, 
pN stage, or PD-L1 expression in tumor-infiltrating immune cells. One hundred ninety-seven 
patients (77%) had high Ki-67 LI. High Ki-67 LI was associated with TNM stage III (P=0.031), 
positive p53 expression (P=0.031), and negative PD-L1 expression (P=0.003). There was no 
significant association between Ki-67 LI and other clinicopathologic parameters. Although Ki-67 
labeling correlated with PD-L1 expression (P=0.031), there was no association between p53 and 
PD-L1 expression (P=0.308). Furthermore, we correlated PD-L1 expression in tumor cells with 
p53 and Ki-67 status. No significant correlation was observed (data was not shown). 
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Prognostic Significance of p53, Ki-67 and PD-L1 Expression  
To evaluate whether p53, Ki-67 and PD-L1 expression in CRC correlates with patients’ 
prognosis, Kaplan-Meier survival curves were constructed using five-year recurrence free 
survival (RFS). The five-year RFS rate for patients with PD-L1 positive tumors was 60%, and 
the five-year RFS rate for the PD-L1 negative tumors was 70% (P=0.041, Figure 3A). Our data 
also revealed that both positive p53 expression and high Ki-67 labeling index (LI) in CRC was 
inversely correlated with the five-year RFS (P=0.001 and P=0.003, respectively, Figure 3B, C). 
The five-year RFS rate for the p53-positive/Ki-67 LI-high patients was 53% and for the p53-
negative/Ki-67 LI-low patients was 89% (P<0.001, Figure 3D).  
Furthermore, Kaplan-Meier analysis was performed in stage II and III CRC patients, 
respectively. The analysis of patients with stage II CRC showed that the five-year RFS rate for 
the p53 positive group was 76.7%, which was significantly lower than 91.5% observed for the 
p53 negative group (P=0.035, Figure 4A). No significant association between Ki-67 LI or 
combined p53-Ki-67 status and prognosis was observed in our analysis (P=0.371 and P=0.086, 
respectively, Figure 4B, C). The analysis of patients with stage III CRC showed that the five-
year RFS rate for the p53 positive group was 55.4%, which was significantly lower than 77.8% 
observed for the p53 negative group (P=0.006, Figure 4D). The five-year RFS rate for the Ki-67 
LI-low group was 59.1%, which was significantly lower than 90% observed for the Ki-67 LI-
high group (P=0.013, Figure 4E). The five-year RFS rate for the p53-positive/Ki-67 LI-high 
patients was 53% and for the p53-negative/Ki-67 LI-low patients was 89% (P=0.002, Figure 4F). 
However, PD-L1 expression was not a strong prognostic marker in patients with CRC stratified 
by stages (P=0.494 and P=0.073, respectively).   
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Next, we examined whether p53, Ki-67 and PD-L1 expression were independent 
prognostic markers for CRC. In univariate Cox regression analysis, positive p53 (P=0.001) 
expression, high Ki-67 LI (P=0.006), increased PD-L1 (P=0.044) expression, higher pathologic 
TNM stage (P<0.001), recto-sigmoid location (P=0.026), LVI (P=0.007), and greater tumor size 
(P=0.013) were significantly related to shorter RFS (Table 2). In multivariate Cox regression 
analysis of these parameters, positive p53 expression (P=0.017, HR 2.370, 95 % CI 1.167-4.811), 
Ki-67 LI-high (P=0.025, HR 2.759, 95 % CI 1.136-6.704) and TNM stage (P=0.029, HR 1.978, 
95 % CI 1.071-3.653) were independent prognostic factors (Table 2). Separate Cox regression 
analysis in stage II and III CRC patients is provided in Table 3 and Table 4. Our results 
indicated that high Ki-67 LI was an independent prognostic marker for RFS in stage III CRC 
(P=0.015, HR 6.919, 95 % CI 1.464-32.703); however, LVI was the only significant prognostic 
marker for RFS in stage II CRC (P=0.045, HR 4.160, 95 % CI 1.032-16.767).  
 
Discussion 
Current prognostic indicators are still ineffective for identifying stage II and III CRC 
patients with high risk of recurrence after resection with curative intent. Current parameters also 
cannot reliably identify patients who are unlikely to recur after surgery alone. In the present 
study, we evaluated the immunophenotypes of 254 CRCs, and correlated these findings with the 
patients’ clinical outcomes. We found that PD-LI, Ki-67, and p53 staining each had individual 
significant prognostic value for patients with stage II and III CRC. However, the combination of 
p53 and Ki-67 labeling is superior to any individual markers for predicting the outcome for CRC 
patients after complete resection, especially for those patients who are positive or negative for 
both immunohistochemical stains.  
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This is the first study, to our knowledge, investigating these three markers in consecutive 
patients from a single, well-defined cohort of CRC radical resection patients with long-term 
follow-up. Mutations of the TP53 tumor suppressor gene play a pivotal role in the progression of 
CRC. P53 alteration might, therefore, represent a clinically useful marker of prognosis. Many 
studies have investigated TP53 gene mutations in CRC, but there is still controversy regarding 
the significance of mutation or the clinical validity of p53 expression for prognosis. In a pooled 
analysis of prognostic value studies from for p53 alteration 4416 CRC patients in 28 published 
studies, neither p53 overexpression nor TP53 mutation emerged as a powerful indicator of 
treatment success(24). However, another analysis of TP53 mutations from 3,583 CRC patients 
being followed by 25 different research groups in 17 countries identified tumor site, exon 5 
mutation, and adjuvant treatment as important factors in determining the prognostic significance 
of TP53 genetic alteration for any stage CRC (25). Available data about the prognostic value of 
p53 alteration between individual studies are inconclusive (26, 27), in large part due to the 
variability between institutions of systematic parameters such as patient selection, amount of 
tissue studied, and variation in immunostaining criteria.  
In this study, all patients were consecutive CRC surgery patients from a single institution 
with a pathologic stage of II or III. We performed ROC analysis to determine the most 
discriminatory cutoff score for p53 expression. For the data in this study an H-score ≥ 35 defined 
positive p53 expression; and an H-score <35 defined negative p53 expression. In our patients, the 
prevalence of positive p53 expression was 63.0%. Positive p53 staining was associated with 
increased tumor size and high Ki-67 LI. In view of different patterns of immunoexpression 
associated with mutant TP53(28), further research is required to correlate p53 expression in CRC 
with mutational analysis in order to establish practical cutoff scores, which can be used to infer 
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the presence of a TP53 mutation. Our study revealed that positive p53 expression in stage II and 
III CRC was inversely correlated with the five-year RFS. Multivariate analysis indicated that 
positive p53 expression independently predicted poor prognosis of CRC patients. Therefore, 
patients with high p53 expression need more aggressive treatment and close follow-up to reduce 
the risk of relapse or metastasis.  
Many studies have shown a predictive role of Ki-67 in various human malignancies, 
including breast cancer, gastrointestinal stromal tumors, and gastrointestinal neuroendocrine 
tumors (29, 30). Earlier studies have emphasized predictive and prognostic roles for BRAF 
mutation in CRC in association with high Ki-67 proliferative index (31, 32). One early 
retrospective investigation of 465 patients from 5 collaborative adjuvant chemotherapy trials 
failed to find association between clinical outcome and Ki-67 staining. However, these 
investigators did find that positive p53 staining correlated with responsiveness to chemotherapy 
and increased survival in the adjuvant chemotherapy treatment group (11). High Ki-67 LI, low 
thymidylate synthase staining intensity and positive p53 staining were significantly correlated, 
but do not appear to be independent predictive variables (11). In our study, high Ki-67 LI was 
associated with advanced TNM stage, p53 overexpression, and PD-L1 expression. Kaplan-Meier 
analysis revealed that high Ki-67 LI in stage II and III CRC was inversely correlated with the 
five-year RFS. Multivariate analysis indicated that high Ki-67 LI independently predicted poor 
prognosis of CRC patients. Patients with high Ki-67 LI require more aggressive treatment and 
active surveillance.  
When patients were further divided into stage II and III disease, Kaplan-Meier analysis 
revealed that the five-year RFS rate for the p53 positive group was significantly lower than the 
p53 negative group in stage II CRC. There was a trend toward a high Ki-67 LI correlation with 
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shorter RFS. The five-year RFS rates for the p53-positive/high Ki-67 LI group were significantly 
lower than the p53-negative/low Ki-67 LI group in stage III CRC. In addition, by multivariate 
analysis we found that LVI was the significant prognostic marker for RFS in stage II CRC and 
high Ki-67 LI was the independent prognostic marker in stage III CRC. Over the years, several 
high-risk clinical features, including T4 primary tumors, poorly differentiated tumors, 
perforation and/or obstruction, LVI, PNI, and less than 12 lymph nodes examined (33), have 
been identified to support the role of adjuvant chemotherapy for stage II CRC. Our study 
confirmed the independent prognostic value of LVI for the clinical outcome in stage II CRC. We 
also demonstrated the prognostic importance of Ki-67 LI in stage III CRC.  
Discrepancies between our study and previous negative studies for association between 
Ki-67 or p53 and prognosis or survival may be attributed to the differences in study design, 
sample size, ethnic populations and stain scoring rules. One limitation of our study is the small 
size of arrayed samples. The main concern is that due to tumor heterogeneity, biomarker scores 
obtained from small TMA cores may not accurately reflect scores obtained from whole slide 
tissue sections. Given this limitation, further research is warranted to determine the efficacy of 
TMA in reflecting the prognostic value of different biomarkers. Studies have also shown that 
mismatch-repair deficient cancers are predicted to a very large number of mutation-associated 
neoantigens that might be recognized by the immune system (34, 35). PD-1 blockade was an 
effective treatment for CRC patients with mismatch-repair deficient tumors (36). Further studies 
are needed to assess the potential for combining microsatellite instability (MMI) status and other 
clinical features or biomarkers to predict prognosis in CRC.  
PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients 
with stage II and III CRC. Moreover, combining p53 H-score ≥ 35 and Ki-67 LI ≥ 20% identifies 
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patients at high risk of recurrence. Such information may potentially be used clinically to guide 
patient management. 
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Figure Legends 
Figure 1: p53 and Ki-67 expression in colorectal cancer. (A) Photomicrograph showing high 
level of p53 expression (IHC, ×200). (B) Photomicrograph showing high Ki-67 labelling index 
(LI) (IHC, ×200). (C) Photomicrograph showing high level of p53 expression (IHC, ×200). (D) 
Photomicrograph showing low Ki67 LI (IHC, ×200). 
 
Figure 2: Receiver operating characteristic curves for p53 with recurrence free survival (A) and 
stages (B). AUC, the area under the curve.  
 
Figure 3: Kaplan-Meier survival analysis for all stages of colorectal cancer patients. Recurrence-
free survival according to (A) PD-L1 expression (positive vs. negative), (B) Ki-67 labelling 
index (high vs. low), (C) p53 expression (positive vs. negative), and (D) combined p53-Ki-67 
status.   
 
Figure 4: Kaplan-Meier survival analysis for stage II and stage III colorectal cancer patients, 
respectively. Recurrence-free survival according to (A, D) p53 expression (positive vs. negative), 
(B, E) Ki-67 labelling index (high vs. low), and (C, F) combined p53-Ki-67 status.   
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Figure 4 
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Table 1 Correlation of p53 and Ki67 expression with clinicopathologic features in 254 colorectal cancer (CRC) patients   
    p53 expression (%)   χ² test Ki-67 expression (%) χ² test p53+Ki-67 expression (%)   χ² test 
Clinicopathologic features n   Positive Negative 
 
P value High LI       Low LI P value  Positive       Negative   P value 
 Gender 
  
   0.630       0.202       0.567  
  Male 160 99 (61.9%) 61 (38.1%)   120 (75.0%) 40 (25.0%)    86 (53.8%) 74 (46.3%)    
  Female 94 61 (64.9%) 33 (35.1%)   77 (81.9%) 17 (18.1%)    54 (57.4%) 40 (42.6%)    
Age（years）        0.357     0.185      0.492  
  <60 104 69 (66.3%) 35 (33.7%)   85 (81.7%) 19 (18.3%)    60 (57.7%) 44 (42.3%)    
  ≥60 150 91 (60.7%) 59 (39.3%)   112 (74.7%) 38 (25.3%)    80 (53.3%) 70 (46.7%)    
Tumor size (cm)      0.001*     0.211      0.008*  
  <5 169 118 (69.8%) 51 (30.2%)   135 (79.9%) 34 (20.1%)    103 (60.9%) 66 (39.1%)    
  ≥5 85 42 (49.4%) 43 (50.6%)   62 (72.9%) 23 (27.1%)    37 (43.5%) 48(56.5%)    
Location       0.615     0.770      0.987  
  Colon 138 85 (61.6%) 53 (38.4%)   108 (78.3%) 30 (21.7%)    76 (55.1%) 62 (44.9%)    
  Rectum 116 75 (64.7%) 41 (35.3%)   89 (76.7%) 27 (23.3%)    64 (55.2%) 52(44.8%)    
Differentiation
 a
       0.308     0.900      0.386  
  High grade 208 128 (61.5%) 80 (38.5%)   161 (77.4%) 47 (22.6%)    112 (53.8%) 96 (46.2%)    
  Low grade 46 32 (69.6%) 14 (30.4%)   36 (78.3%) 10 (21.7%)    28 (60.9%) 18 (39.1%)    
TNM stage  
  
 0.470     0.031
*
    0.741  
  II 133 81 (60.9%) 52 (39.1%)   96 (72.2%) 37 (27.8%)    72 (54.1%) 61 (45.9%)    
  III 121 79 (65.3) 42 (34.7%)   101 (83.5%) 20 (16.5%)    68 (56.2%) 53 (43.8%)    
LVI     0.473     0.131    0.548  
  Positive 33 19 (55.6%) 14 (42.4%)   27 (81.8%) 6 (18.2%)    17 (51.5%) 16 (48.5%)    
  Negative 140 90 (64.3%) 50 (35.7)   96 (68.6%) 44 (31.4%)    64 (45.7%) 76 (54.3%)    
PNI     0.259     0.186    0.089  
  Positive 28 15 (53.6%) 13 (46.4%)   17 (60.7%) 11 (39.3%)    9 (32.1%) 19 (67.9%)    
  Negative 145 94 (64.8%) 51 (35.2%)   106 (73.1%) 39 (26.9%)    72 (49.7%) 73 (50.3%)    
pT stage     0.946     0.069    0.596  
  T2+T3 129 81 (62.8%) 48 (37.2%)   94 (72.9%) 35 (27.1%)    69 (53.5%) 60 (46.5%)    
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    p53 expression (%)   χ² test Ki-67 expression (%) χ² test p53+Ki-67 expression (%)   χ² test 
Clinicopathologic features n   Positive Negative 
 
P value High LI       Low LI P value  Positive       Negative   P value 
  T4 125 79 (63.2%) 46 (36.8%)   103 (82.4%) 22 (17.6%)    71 (56.8%) 54 (43.2%)    
pN stage       0.278     0.061      0.119  
  N0 134 82 (61.2%) 52 (38.8%)    97 (72.4%) 37 (27.6%)    73 (54.5%) 61 (45.5%)    
  N1 69 41 (59.4%) 28 (40.6%) 
  
55 (79.7%) 14 (20.3%)    33 (47.8%) 36 (52.2%)    
  N2 51 37 (72.5%) 14 (27.5%)   45 (88.2%) 6 (11.8%)    34 (66.7%) 17 (33.3%)    
Ki-67     0.031
*
           
  Low 57 29 (50.9%) 28 (49.1%)             
  High 197 131 (66.5%) 66 (33.5%)             
p53          0.031
*
      
  Negative 94     66 (70.2%) 28 (29.8%)         
  Positive 160     131 (81.9%) 29 (18.1%)         
PD-L1
b
     0.308     0.003
*
    0.029
*
 
  Positive 46 32 (69.6%) 14 (30.4%)   43 (93.5%) 3 (6.5%)    32 (69.6%) 14 (30.4%)   
  Negative 208 128 (61.5%) 80 (38.5%)   154 (74.0%) 54 (26.0%)    108 (51.9%) 100 (48.1%)                 
 
Note. P value was obtained from χ2 test. Abbreviations: LI, labeling index; LVI, lymphovascular invasion; PNI, perineural invasion.  
a
Differentiation: well and moderately differentiated tumors were designated as low grade, and poorly differentiated tumors were  
designated as high grade. 
b
PD-L1: PD-L1 expression in tumor-infiltrating immune cells. 
*
Statistically significant.  
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Table 2 Univariate and multivariate analysis of variables on recurrence free survival in 254 colorectal cancer patients 
 
Parameters 
 Univariate    Multivariate 
HR 95% CI P value   HR 95% CI P value 
Gender 0.827 0.500 to 1.367 0.459   0.740 0.391 to 1.400 0.355 
Age 0.835 0.517 to 1.348 0.461   0.555  0.304 to 1.011 0.054 
Location
a
 1.730  1.069 to 2.798 0.026*   1.480 0.812 to 2.699 0.200 
Size 0.474 0.263 to 0.853 0.013*   0.937 0.463 to 1.899 0.857 
LVI 2.279 1.247 to 4.166 0.007
*
   1.926 0.960 to 3.866 0.065 
PNI 1.444 0.723 to 2.883 0.298   1.876 0.840 to 4.188 0.125 
Differentiation 0.848 0.444 to 1.617 0.616   0.571 0.241 to 1.352 0.203 
TNM 
PD-L1
b
 
2.817 
1.739 
1.693 to 4.689 
1.015 to 2.982 
<0.001* 
0.044* 
  1.978 
1.415 
1.071 to 3.653 
0.732 to 2.735 
0.029* 
0.302 
p53 2.771 1.513 to 5.074 0.001*   2.370 1.167 to 4.811 0.017* 
Ki-67 3.274 1.416 to 7.569 0.006*   2.759 1.136 to 6.704 0.025* 
           Note. Abbreviations: CI, confidence interval; HR, hazard ratio, determined by Cox proportional hazard models; LVI,    
           lymphovascular invasion; PNI, perineural invasion. 
a 
Location: colon versus rectum (colon cancer patients had better   
           survival). 
b
PD-L1: PD-L1 expression in tumor-infiltrating immune cells. 
*
 Statistically significant.   
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Table 3 Univariate and multivariate analysis of variables on recurrence free survival in 133 stage II colorectal cancer patients. 
 
Parameters 
 Univariate    Multivariate 
HR 95% CI P value   HR 95% CI P value 
Gender 1.763 0.761 to 4.082 0.186   1.717 0.640 to 4.605 0.283 
Age 1.377 0.578 to 3.283 0.470   1.312  0.478 to 3.603 0.054 
Location 1.502  0.651 to 3.465 0.340   1.672 0.590 to 4.737 0.334 
Size 0.220 0.065 to 0.745 0.015
*
   0.420 0.105 to 1.675 0.219 
LVI 3.714 1.226 to 11.256 0.020
*
   4.160 1.032 to 16.767 0.045
*
 
PNI 1.486 0.493 to 4.484 0.482   0.719 0.146 to 3.545 0.685 
Differentiation 1.241 0.458 to 3.364 0.672   1.325 0.301 to 5.837 0.710 
PD-L1
a
 1.413 0.521 to 3.831 0.497   0.863 0.229 to 3.254 0.828 
p53 3.027 1.024 to 8.945 0.045
*
   2.630 0.710 to 9.743 0.148 
Ki-67 1.725 0.584 to 5.098 0.324   2.226 0.670 to 7.400 0.192 
  
           Note. Abbreviations: CI, confidence interval; HR, hazard ratio, determined by Cox proportional hazard models; LVI,    
           lymphovascular invasion; PNI, perineural invasion. 
a
PD-L1: PD-L1 expression in tumor-infiltrating immune cells.  
           
*
Statistically significant.    
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Table 4 Univariate and multivariate analysis of variables on recurrence free survival in 121 stage II colorectal cancer patients 
 
Parameters 
 Univariate    Multivariate 
HR 95% CI P value   HR 95% CI P value 
Gender 0.583 0.296 to 1.150 0.120   0.360 0.132 to 0.979 0.045
*
 
Age 0.559 0.313 to 0.998 0.049
*
   0.280  0.125 to 0.629 0.002
*
 
Location 1.681  0.930 to 3.041 0.086   1.785 0.791 to 4.028 0.163 
Size 0.829 0.421 to 1.632 0.587   1.744 0.726 to 4.191 0.213 
LVI 1.444 0.696 toc2.996 0.324   1.406 0.608 to 3.252 0.426 
PNI 1.471 0.605 to 3.579 0.395   3.028 0.983 to 9.326 0.054 
Differentiation 0.731 0.310 to 1.728 0.476   0.318 0.099 to 1.024 0.055 
PD-L1
a
 1.784 0.935 to 3.407 0.079   1.547 0.689 to 3.473 0.291 
P53 2.658 1.280 to 5.518 0.009
*
   1.993 0.843 to 4.712 0.116 
Ki-67 4.975 1.204 to 20.552 0.027
*
   6.919 1.464 to 32.703 0.015
*
 
         Note. Abbreviations: CI, confidence interval; HR, hazard ratio, determined by Cox proportional hazard models; LVI,    
      lymphovascular invasion; PNI, perineural invasion. 
a
PD-L1: PD-L1 expression in tumor-infiltrating immune cells.    
          
*
Statistically significant.   
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Highlights 
 PD-L1, p53, and Ki-67 staining individually had prognostic value for CRC patients. 
 p53, Ki-67 and TNM stage were independent prognostic factors in CRC.  
 High expression of both p53 and Ki-67 predicted poor prognosis for CRC patients.   
